Cost-effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression

被引：5

作者：

Aguiar, Pedro, Jr. ^{[1
]}

Perry, Luke A. ^{[2
]}

Lopes, Gilberto L., Jr. ^{[3
]}

机构：

[1] Univ Fed Sao Paulo, Oncol & Hematol Dept, Clin Oncol Sect, Sao Paulo, Brazil

[2] Monash Univ Sch Med, Fac Med Nursing & Hlth Sci, Melbourne, Vic, Australia

[3] Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL USA

来源：

LUNG CANCER MANAGEMENT | 2016年 / 5卷 / 03期

关键词：

cost-effectiveness; health technology assessment; immunotherapy; lung cancer;

D O I：

10.2217/lmt-2016-0016

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

引用

页码：119 / 122

页数：4

共 17 条

[1] Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents: A meta-analysis [J].

Abdel-Rahman, Omar .

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 101 :75-85

[2] The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis [J].

Aguiar, Pedro N., Jr. ;

Santoro, Ilka Lopes ;

Tadokoro, Hakaru ;

Lopes, Gilberto de Lima ;

Filardi, Bruno Andraus ;

Oliveira, Pedro ;

Mountzios, Giannis ;

de Mello, Ramon Andrade .

IMMUNOTHERAPY, 2016, 8 (04) :479-488

[3] Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. [J].

Aguiar, Pedro Nazareth ;

Tadokoro, Hakaru ;

Barreto, Carmelia Maria Noia ;

Santoro, Ilka Lopes ;

De Mello, Ramon Andrade ;

Babiker, Hani M. ;

Avancha, Kiran ;

Lopes, Gilberto .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)

[4]

[Anonymous], GLOB EC COST CANC

[5]

Bauer TM, 2015, J CLIN ONCOL, V33

[6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[7]

Borghaei H, 2016, J CLIN ONCOL, V34

[8] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[9] Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1 [J].

Chen, Daniel S. ;

Irving, Bryan A. ;

Hodi, F. Stephen .

CLINICAL CANCER RESEARCH, 2012, 18 (24) :6580-6587

[10] Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].

Garon, Edward B. ;

Rizvi, Naiyer A. ;

Hui, Rina ;

Leighl, Natasha ;

Balmanoukian, Ani S. ;

Eder, Joseph Paul ;

Patnaik, Amita ;

Aggarwal, Charu ;

Gubens, Matthew ;

Horn, Leora ;

Carcereny, Enric ;

Ahn, Myung-Ju ;

Felip, Enriqueta ;

Lee, Jong-Seok ;

Hellmann, Matthew D. ;

Hamid, Omid ;

Goldman, Jonathan W. ;

Soria, Jean-Charles ;

Dolled-Filhart, Marisa ;

Rutledge, Ruth Z. ;

Zhang, Jin ;

Lunceford, Jared K. ;

Rangwala, Reshma ;

Lubiniecki, Gregory M. ;

Roach, Charlotte ;

Emancipator, Kenneth ;

Gandhi, Leena .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028

← 1 2 →